Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byHilary Blair Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.122
Figure 4 Recurrent genetic alterations affecting key pathways involved in multiple myeloma Figure 4 | Recurrent genetic alterations affecting key pathways involved in multiple myeloma. Signalling pathways and processes known to be affected in multiple myeloma are involved in the NF-κB, MAPK, plasma-cell differentiation, cell cycle and DNA-damage repair pathways. In this diagram, frequently mutated genes with well-established roles in these signalling pathways have been depicted representing the proteins they encode. Manier, S. et al. (2016) Genomic complexity of multiple myeloma and its clinical implications Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Presented By Sham Mailankody at 2016 ASCO Annual Meeting

Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Signalling pathways and physiological domains that are

Figure 2 Signalling pathways and physiological domains that are
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 3 The cell cycle and the role of CDK4/6 inhibition

Figure 3 The cell cycle and the role of CDK4/6 inhibition
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 4 Possible combination therapies CDK4/6 inhibitors
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Similar presentations

Ads by Google